SLC18A3 and Alzheimer disease: In addition, choline acetyltransferase (ChAT) and vesicular acetylcholine transporter (VAChT) expression was found to be upregulated, which was associated with an increase in cellular Ach levels and was beneficial in inhibiting AD progression [40].